Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | DBH | P09172 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28151235 | 0.86 | TUBB1 (0.41) | TUBB1ACACBDBHSMN1; SMN2CACNA1H | |
| SCHEMBL2126253 | 0.85 | THRB (0.46) | TUBB1DBHPOLB | |
| SCHEMBL14939021 | 0.83 | TUBB1 (0.39) | TUBB1ACACBDBH | |
| SCHEMBL2126802 | 0.83 | HSP90AB1 (0.56) | TUBB1ACACBDBHSMN1; SMN2CACNA1H | |
| SCHEMBL5511607 | 0.79 | MAOB (0.46) | CYP3A4POLB | |
| SCHEMBL17730733 | 0.79 | CACNA1H (0.44) | ACACBSMN1; SMN2CACNA1HCACNA1GCACNA1I | |
| SCHEMBL18324045 | 0.78 | TDP1 (0.50) | CYP3A4TUBB1POLB | |
| SCHEMBL2307800 | 0.78 | PTGS2 (0.55) | CYP3A4SMN1; SMN2POLB | |
| SCHEMBL21957025 | 0.78 | HSP90AB1 (0.38) | CYP3A4POLB | |
| SCHEMBL4660697 | 0.78 | DBH (0.38) | TUBB1ACACBDBHSMN1; SMN2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045463-B2 | Phenyl ethynyl derivatives as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2015-06-02 | — | — | US | disclosed |
| US-9045463-B2 | Phenyl ethynyl derivatives as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2015-06-02 | — | — | US | disclosed |
| US-20120136027-A1 | Phenyl Ethynyl Derivatives As Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2012-05-31 | — | — | US | disclosed |
| US-20120136027-A1 | Phenyl Ethynyl Derivatives As Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2012-05-31 | — | — | US | disclosed |
| WO-2011015657-A1 | PHENYL ETHYNYL DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-02-10 | — | — | WO | disclosed |
| US-20030143701-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. | 2003-07-31 | — | — | US | disclosed |
| EP-0924194-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6528686-B1 | Reacting primary amine and ketone functionalized derivatives; catalytically reducing | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-0924193-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0939134-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6114582-A | DECYCLIZATION TO FORM A CHEMICAL INTERMEDIATE FOR PRODUCING AN ANTI-OBESITY AGENT AND ANTIDIABETIC AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0654534-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2000-03-01 | — | — | EP | disclosed |
| EP-0939134-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0924194-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-4622342-A | HYPOGLYCEMIC AGENTS, ANTIOBESITY | BEECHAM GROUP P.L.C. (GB) | 1986-11-11 | — | — | US | disclosed |
| EP-0070134-B1 | SECONDARY PHENYL ETHANOL AMINES AND THEIR PHARMACEUTICAL USE | BEECHAM GROUP PLC (GB) | 1985-11-13 | — | — | EP | disclosed |
| EP-0070134-A1 | Secondary phenyl ethanol amines and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136027-A1 | Phenyl Ethynyl Derivatives As Hepatitis C Virus Inhibitors | HAVCR2, ZC3HAV1, EIF2AK2 | CYP3A4 168/4885TUBB1 2634/4885ACACB 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.